Programmed death-ligand 2 (PD-L2) expression in bladder cancer

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al. · CA A Cancer Journal for Clinicians · 2018 · 87.7K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

Spencer C. Liang, Yvette Latchman, Janet E. Buhlmann et al. · European Journal of Immunology · 2003 · 629 citations

Life Sciences, Endocrinology, Immunology +17

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

Jennifer H. Yearley, Christopher J. Gibson, Ni Yu et al. · Clinical Cancer Research · 2017 · 604 citations

Life Sciences, Immunology, Oncology +17

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

W. Joost Lesterhuis, Cornelis J.A. Punt, Stanleyson V. Hato et al. · Journal of Clinical Investigation · 2011 · 347 citations · Full text

Medicine, Immunology, Oncology +17

PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes

Matthew W. Rosenbaum, Jacob R. Bledsoe, Vicente Morales‐Oyarvide et al. · Modern Pathology · 2016 · 307 citations · Full text

Medicine, Oncology, Pathology +17